Feline Chronic Upper Respiratory Infections and the Gut Microbiota

Veterinary teams in Australia are increasingly interested in how the gut microbiome may influence recurrent respiratory illness in cats. The webinar, Gut Microbiota and Feline Chronic Upper Respiratory Tract Infections: A Pilot Study, examines whether cats with persistent upper respiratory signs differ microbiologically from healthy controls and whether those differences can guide future clinical research. It forms part of ActivBiome’s on-demand education for veterinary professionals, developed with researchers and institutions including Harvard T.H. Chan School of Public Health, Texas A&M University and the University of Vienna.

For Australian practices, the topic is immediately relevant: cats are among the country’s most common companion animals, while crowding in apartments, boarding catteries and shelters can coincide with outbreaks. The pilot is an early investigation, not a diagnostic algorithm. Its value lies in connecting gastrointestinal and respiratory health while exposing environmental and treatment factors that clinicians must consider.

What the pilot study examined

Chronic upper respiratory disease in cats generally describes sneezing, ocular or nasal discharge, conjunctivitis and oral ulceration that persists or returns over several weeks. Feline herpesvirus type 1 and feline calicivirus are central differential diagnoses, with secondary bacterial infection sometimes complicating the picture. A microbiome result cannot replace viral PCR, culture where indicated, or assessment for nasal obstruction and dental disease.

The pilot asked whether affected cats showed different faecal microbial-community profiles from comparison cats. Molecular profiling was used to examine diversity and the abundance of bacterial groups rather than search for one explanatory organism. Age, diet, recent antibiotics, stress, housing and treatment can all alter a feline microbiome, so differences between groups must be interpreted as associations rather than proof of cause.

Reading the microbiome findings

Microbiome data are read at several levels. Alpha diversity describes variation within an individual sample, while beta diversity compares the overall community structure between groups. Taxonomic findings may point towards particular organisms, but they do not by themselves show whether those organisms produce metabolites, stimulate immunity or merely accompany disease.

For a veterinary audience, the important conclusion is that dysbiosis can be a useful research signal without being a diagnostic label for feline respiratory disease. Small samples, variable clinical phenotypes and differences in husbandry can generate apparent associations, while a stool sample is many steps removed from the nasal mucosa. Confirmatory work needs larger, well-characterised cohorts, consistent sampling and, ideally, direct airway comparison.

Linking the gut and respiratory tract

The gut and respiratory tract are separate mucosal surfaces linked by circulation, immune-cell trafficking and microbial metabolites. A disturbed intestinal community may alter barrier integrity and the tone of local immune responses. This gut–respiratory axis is a plausible framework for studying recurrent feline disease, but a faecal association does not demonstrate that intestinal dysbiosis caused upper respiratory signs.

Short-chain fatty acids, bile acids and tryptophan-derived compounds are among the pathways under investigation. They can affect epithelial cells and immune pathways, potentially changing susceptibility to secondary infection or viral reactivation. Yet direction matters: respiratory illness may lead to altered intake and medication, which then changes the gut. Diet and stress can act on both systems at once, so microbiome findings should be treated as one part of the clinical picture.

Considering probiotics in clinical care

Clinical workup should therefore remain disease-focused. Confirming feline herpesvirus, calicivirus or relevant bacterial involvement, assessing severity and identifying dental, nasal or anatomical causes remain central. A microbiome panel may add research insight, but it does not establish why an individual cat is sneezing or justify delaying established care.

A companion ActivBiome explainer on probiotic yeast in dogs illustrates how Saccharomyces boulardii may influence the gut environment and immune signalling. Those mechanisms make yeast probiotics biologically plausible adjuncts, yet evidence from dogs cannot simply be transferred to cats with chronic upper respiratory disease. Efficacy should be judged by strain-specific, condition-specific data rather than a generic “probiotic” label.

For cats, a probiotic may be considered as part of a broader supportive plan when owners understand that it is not an antiviral medicine and may not prevent recurrence. Product quality, viable organism count and storage matter. Australian summer heat can stress unrefrigerated distribution and home storage, so following the labelled temperature instructions and sourcing through the veterinary channel are practical safeguards.

Applying the evidence in Australia

Australian application also involves geography and housing. In Sydney and Melbourne, high-rise living and dense urban environments can increase exposure to stress and respiratory pathogens; in Brisbane, Adelaide and Perth, hot summers, air-conditioning and variable humidity shape indoor respiratory environments. Long distances between metropolitan centres, regional clinics and referral practices can complicate specialist review and couriered sample logistics, making consistent protocols especially valuable.

Australia’s pet-food market is mature, with veterinary diets and supplements sold through clinics, specialist retailers and online channels. The educational resource library provides webinar recordings and downloadable material on microbiome science, chronic enteropathies and dysbiosis for teams seeking a structured way to continue professional learning and discuss evidence with clients.

Customs and biosecurity can also shape what is available. When clinicians, retailers or researchers import cultures, biological samples or feed ingredients, the Department of Agriculture, Fisheries and Forestry’s BICON system may require permits, documentation and biosecurity clearance. Product availability alone does not establish suitability, and any therapeutic claim must still meet Australian consumer and animal-feed requirements. The most defensible position is to use pilot findings to refine immune–gut hypotheses, retain standard respiratory diagnostics and assess microbiome-directed adjuncts with strain-specific evidence and careful follow-up.